NCT03320265 is a Phase 2 clinical trial of PC-mAb in Arterial Inflammation, sponsored by Athera Biotechnologies AB.

Who is sponsoring NCT03320265?

NCT03320265 is sponsored by Athera Biotechnologies AB.

What drugs are being tested in NCT03320265?

Interventions in NCT03320265: PC-mAb, Placebo.

What condition does NCT03320265 study?

NCT03320265 studies Arterial Inflammation, Cardiovascular Diseases.

Is NCT03320265 still recruiting?

NCT03320265 is currently terminated. Last updated 6 July 2018.

Last reviewed 2018-07-06 · How we verify

NCT03320265

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a

Terminated Phase 2 Last updated 6 July 2018

What this trial tests

Phase 2 trial testing PC-mAb in Arterial Inflammation in 10 participants. Terminated before completion.

Timeline

11 October 2017

Primary endpoint
19 March 2018

3 July 2018

Quick facts

Lead sponsor	Athera Biotechnologies AB
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	10
Start date	11 October 2017
Primary completion	19 March 2018
Estimated completion	3 July 2018
Sites	2 locations across Sweden, Netherlands

Drugs / interventions tested

PC-mAb — full drug profile →
Placebo

Conditions studied

Arterial Inflammation — all drugs for Arterial Inflammation →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Athera Biotechnologies AB — full company profile →

Who can join

50 and older, any sex, with Arterial Inflammation or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects, including endothelial dysfunction and migration of white blood cells into the vessel wall, which results in increased risk of cardiovascular events. This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Athera Biotechnologies AB trials

Trials by the same sponsor.

NCT03991143 — Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03320265 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Athera Biotechnologies AB
Last refreshed: 6 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03320265.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing